Incidence rates for mortality were 0.14, 2.04, and 8.45 per 100 person year for MASH, compensated cirrhosis, and decompensated cirrhosis, respectively
Other Adverse Reactions Gastrointestinal Adverse Reactions In the pool of 5 glycemic control, placebo-controlled adult clinical trials, withdrawals due to gastrointestinal adverse reactions, occurred in 4.3% of liraglutide injection-treated patients and 0.5% of placebo-treated patients
Administration of DSS in drinking water also resulted in the induction of a reproducible pro-inflammatory response, limited to the colon and characterized by lesions, loss of crypts, and infiltration of granulocytes, similar to PGN administration (Okayasu et al
Athletes are not sanctioned for testing positive for monitoring-only substances
What we do know: -Strong preclinical evidence suggests GLP-1RAs reduce drug/alcohol intake, motivation, and relapse
That is not a win